Steris Plc Form 8-K Summary: Redomiciliation Completion
Business Context and Reporting Period
Date of Report: March 28, 2019
Company: STERIS plc (formerly STERIS UK)
Event: Completion of redomiciliation from England and Wales to Ireland. STERIS plc (Ireland) became the ultimate holding company of STERIS UK via a court-approved scheme of arrangement. STERIS UK is now a wholly-owned subsidiary.
Key Financial Metrics and Debt
This filing reports on a corporate restructuring event and does not contain operational financial results (revenue, profit, cash flow, or margins) for the period. However, it discloses the following debt obligations outstanding as of December 31, 2018:
- Credit Agreement Borrowings: Approximately $336 million and €25 million.
- Outstanding Notes: Approximately $676 million, €99 million, and £75 million.
Liquidity and Capital Structure: The filing notes the redemption of STERIS UK's redeemable preference shares on March 28, 2019. New STERIS Ireland shares were issued to shareholders on a one-for-one basis with cancelled STERIS UK shares.
Material Changes Versus Prior Period
- Corporate Jurisdiction: The registrant changed from an English public limited company to an Irish public limited company.
- Debt Agreements: The Credit Agreement and various Note Purchase Agreements were amended and restated effective March 28, 2019. STERIS Ireland is now designated as the Borrower, Guarantor, and Reporting Entity for these facilities.
- Board Composition: All directors of STERIS UK became directors of STERIS Ireland. Two directors (J. Adam Zangerle and Michael J. Tokich) resigned from the STERIS Ireland board effective March 28, 2019.
- Executive Officers: All executive officers of STERIS UK were designated as executive officers of STERIS Ireland with the same positions.
Guidance, Outlook, and Management Commentary
Management Commentary: The filing confirms that the redomiciliation was completed pursuant to a scheme of arrangement. The company states that compensation arrangements for non-employee directors and named executive officers will initially remain consistent with STERIS UK practices.
Equity Incentives: Outstanding equity awards under the 2006 Long-Term Equity Incentive Plan were automatically converted into equivalent awards for STERIS Ireland shares. The Management Incentive Compensation Plan was amended and restated to be assumed by STERIS Ireland.
Severance Plan: A new Senior Executive Severance Plan was adopted to replace the predecessor plan, covering executive officers and other approved employees. Benefits generally include one year of base salary (or two years in conjunction with a Change in Control), prorated incentives, and medical/dental reimbursement.
Risks and Contingencies: The filing does not explicitly list new risks but notes that the company is subject to the information requirements of the Exchange Act as the successor issuer. The definitive proxy statement/prospectus (incorporated by reference) contains additional details on the treatment of equity awards and interests of directors.
Investor Verification Checklist
- Verify the terms of the Amended and Restated Credit Agreement and Note Purchase Agreements to confirm no material changes to borrowing costs or covenants.
- Review the "Explanatory Statement" in the Registration Statement (Form S-4) for a complete description of the redomiciliation scheme.
- Confirm the listing status of STERIS Ireland shares on the NYSE under the symbol "STE."
- Check the specific terms of the new Senior Executive Severance Plan (Exhibit 10.3) for potential liabilities related to executive turnover.
- Review the amended 2006 Long-Term Equity Incentive Plan (Exhibit 10.1) to understand the conversion mechanics for existing awards.